BioAge Labs (NASDAQ:BIOA - Get Free Report) had its target price reduced by equities researchers at Citigroup from $21.00 to $20.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Citigroup's target price indicates a potential upside of 309.84% from the company's current price.
Several other brokerages also recently issued reports on BIOA. Wall Street Zen downgraded shares of BioAge Labs from a "sell" rating to a "strong sell" rating in a research report on Saturday, October 10th. Weiss Ratings raised BioAge Labs from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, October 26th. Jefferies Financial Group set a $21.00 price target on BioAge Labs in a research note on Friday, July 31st. Roth Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of BioAge Labs in a report on Wednesday, September 9th. Finally, UBS Group started coverage on BioAge Labs in a report on Sunday, October 11th. They set a "neutral" rating and a $8.00 target price for the company. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $29.00.
Get Our Latest Stock Analysis on BIOA
BioAge Labs Stock Down 4.3%
Shares of NASDAQ BIOA traded down $0.22 during midday trading on Wednesday, hitting $4.88. 291,945 shares of the company's stock were exchanged, compared to its average volume of 714,784. The firm has a market capitalization of $224.28 million, a PE ratio of -1.92 and a beta of 1.19. BioAge Labs has a 12 month low of $4.81 and a 12 month high of $25.95. The company's 50 day moving average price is $6.43 and its 200 day moving average price is $15.00.
BioAge Labs (NASDAQ:BIOA - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.05). The business had revenue of $0.30 million for the quarter. BioAge Labs had a negative net margin of 1,253.60% and a negative return on equity of 31.42%. On average, equities research analysts anticipate that BioAge Labs will post -2.59 EPS for the current year.
Institutional Investors Weigh In On BioAge Labs
A number of large investors have recently bought and sold shares of BIOA. a16z Capital Management L.L.C. acquired a new position in BioAge Labs in the 3rd quarter worth about $22,923,000. BlackRock Inc. acquired a new stake in shares of BioAge Labs during the second quarter valued at about $69,831,000. Jupiter Topco LLC acquired a new stake in shares of BioAge Labs during the second quarter valued at about $52,597,000. Janus Henderson Group PLC boosted its stake in shares of BioAge Labs by 411.8% during the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company's stock valued at $36,597,000 after purchasing an additional 1,685,063 shares in the last quarter. Finally, Octagon Capital Advisors LP grew its holdings in shares of BioAge Labs by 9.4% during the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company's stock worth $30,573,000 after purchasing an additional 150,000 shares during the last quarter.
BioAge Labs Company Profile
(
Get Free Report)
BioAge Labs is a clinical-stage biopharmaceutical company developing medicines for metabolic diseases by targeting biological pathways associated with aging. Its research platform draws on human data to identify age-related mechanisms that may be relevant to disease and treatment. The company's pipeline includes BGE-102, an investigational oral inhibitor of the NLRP3 protein, which is being developed for metabolic conditions. BioAge previously studied azelaprag, an apelin-receptor agonist, but discontinued its development after safety concerns arose in a clinical trial.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioAge Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioAge Labs wasn't on the list.
While BioAge Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.